{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:33:23Z","timestamp":1794652403912,"version":"4.9.1"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.intimp.2020.106717","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T06:56:09Z","timestamp":1592463369000},"page":"106717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses"],"prefix":"10.1016","volume":"86","author":[{"given":"Tania","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishir K","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106717_b0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10223","key":"10.1016\/j.intimp.2020.106717_b0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"The Lancet"},{"issue":"7798","key":"10.1016\/j.intimp.2020.106717_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106717_b0020","unstructured":"World Health Organization, 2020. WHO Director-General\u2019s remarks at the media briefing on 2019-nCoV on 11 February 2020.Internet] World Health Organization."},{"issue":"10223","key":"10.1016\/j.intimp.2020.106717_b0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.intimp.2020.106717_b0030","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"issue":"10223","key":"10.1016\/j.intimp.2020.106717_b0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2020.106717_b0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"7798","key":"10.1016\/j.intimp.2020.106717_b0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2020.106717_b0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerging Microbes Infect."},{"key":"10.1016\/j.intimp.2020.106717_b0060","series-title":"Coronaviruses","first-page":"1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","author":"Fehr","year":"2015"},{"issue":"10224","key":"10.1016\/j.intimp.2020.106717_b0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"The Lancet"},{"issue":"7461","key":"10.1016\/j.intimp.2020.106717_b0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.intimp.2020.106717_b0075","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41594-019-0334-7","article-title":"Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors","volume":"26","author":"Park","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106717_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song","year":"2018","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0085","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.106717_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.106717_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.intimp.2020.106717_b0100","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.0306446101","article-title":"Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry","volume":"101","author":"Simmons","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2020.106717_b0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Res."},{"key":"10.1016\/j.intimp.2020.106717_b0110","unstructured":"https:\/\/www.who.int\/news-room\/q-a-detail\/q-a-coronaviruses (12.00 PM, 01\/04\/2020)."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.virusres.2007.03.025","article-title":"Animal models and vaccines for SARS-CoV infection","volume":"133","author":"Roberts","year":"2008","journal-title":"Virus Res."},{"issue":"9","key":"10.1016\/j.intimp.2020.106717_b0120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1586\/14760584.2016.1167603","article-title":"Vaccines for the prevention against the threat of MERS-CoV","volume":"15","author":"Du","year":"2016","journal-title":"Expert Rev. Vaccines"},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0125","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg. Infect. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2020.106717_b0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","article-title":"An overview of novel adjuvants designed for improving vaccine efficacy","volume":"38","author":"Bonam","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"19","key":"10.1016\/j.intimp.2020.106717_b0135","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1016\/j.vaccine.2007.01.111","article-title":"Vaccine adjuvants revisited","volume":"25","author":"Aguilar","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106717_b0140","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.106717_b0145","first-page":"2020030464","article-title":"Developing a low-cost and accessible COVID-19 vaccine for global","author":"Hotez","year":"2020","journal-title":"Health. Preprints"},{"key":"10.1016\/j.intimp.2020.106717_b0150","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0264-410X(02)00169-X","article-title":"Mechanisms of stimulation of the immune response by aluminum adjuvants","volume":"20","author":"HogenEsch","year":"2002","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0155","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/IAI.69.2.1151-1159.2001","article-title":"The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism","volume":"69","author":"Ulanova","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2020.106717_b0160","doi-asserted-by":"crossref","unstructured":"Tomljenovic, L. and A Shaw, C., 2011. Aluminum vaccine adjuvants: are they safe?.Current Medicinal Chemistry,18(17), pp.2630-2637.","DOI":"10.2174\/092986711795933740"},{"issue":"4","key":"10.1016\/j.intimp.2020.106717_b0165","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells","volume":"205","author":"Kool","year":"2008","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.intimp.2020.106717_b0170","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/intimm\/dxh143","article-title":"A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice","volume":"16","author":"Takasuka","year":"2004","journal-title":"Int. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106717_b0175","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/104454904323145272","article-title":"Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB\/c mice","volume":"23","author":"Tang","year":"2004","journal-title":"DNA Cell Biol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0180","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.vaccine.2005.06.038","article-title":"Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine","volume":"24","author":"Qin","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12250-018-0009-2","article-title":"Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine","volume":"33","author":"Luo","year":"2018","journal-title":"Virologica Sinica"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-018-0056-7","article-title":"Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus","volume":"7","author":"Deng","year":"2018","journal-title":"Emerging Microbes Infect."},{"issue":"9","key":"10.1016\/j.intimp.2020.106717_b0195","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Human Vacc. Immunotherapeut."},{"issue":"23","key":"10.1016\/j.intimp.2020.106717_b0200","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.106717_b0205","doi-asserted-by":"crossref","unstructured":"Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. 2012. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492"},{"key":"10.1016\/j.intimp.2020.106717_b0210","doi-asserted-by":"crossref","unstructured":"Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, Kase R, Sekiguchi S, Morita K, Hishima T, Suzuki H, Karamatsu K, Yasutomi Y, Shida H, Kidokoro M, Mizuno K, Matsushima K, Kohara M. 2008. Prior immunization with severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. JImmunol181:6337\u20136348.","DOI":"10.4049\/jimmunol.181.9.6337"},{"key":"10.1016\/j.intimp.2020.106717_b0215","first-page":"1","article-title":"The potential danger of suboptimal antibody responses in COVID-19","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106717_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030525","article-title":"Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants","volume":"3","author":"Deming","year":"2006","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.106717_b0225","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.intimp.2020.106717_b0230","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1016\/j.vaccine.2006.01.059","article-title":"A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice","volume":"24","author":"Zhou","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0235","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/vim.2012.0076","article-title":"Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates","volume":"26","author":"Li","year":"2013","journal-title":"Viral Immunol."},{"issue":"38","key":"10.1016\/j.intimp.2020.106717_b0240","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2011.06.111","article-title":"Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2020.106717_b0245","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.vaccine.2007.11.092","article-title":"Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV","volume":"26","author":"Lokugamage","year":"2008","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.intimp.2020.106717_b0250","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2014.04.016","article-title":"Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice","volume":"32","author":"Coleman","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2020.106717_b0255","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Human Vac. Immunotherapeutics"},{"issue":"8","key":"10.1016\/j.intimp.2020.106717_b0260","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.18632\/oncotarget.8475","article-title":"MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.intimp.2020.106717_b0265","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ebiom.2015.08.031","article-title":"Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge","volume":"2","author":"Lan","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2020.106717_b0270","series-title":"Immunopotentiators in Modern Vaccines","first-page":"249","article-title":"MF59: a safe and potent adjuvant for human use","author":"Kommareddy","year":"2017"},{"issue":"5","key":"10.1016\/j.intimp.2020.106717_b0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O\u2019Hagan","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2020.106717_b0280","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 adjuvant: the best insurance against influenza strain diversity","volume":"10","author":"O\u2019Hagan","year":"2011","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.intimp.2020.106717_b0285","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc. Natl. Acad Sci. USA"},{"issue":"12","key":"10.1016\/j.intimp.2020.106717_b0290","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Human Vacc. Immunotherapeut."},{"key":"10.1016\/j.intimp.2020.106717_b0295","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1128\/JVI.00339-16","article-title":"Effects of MF59 adjuvant on induction of isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4+ T cells","volume":"90","author":"Ko","year":"2016","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106717_b0300","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3201\/eid1108.041003","article-title":"SARS vaccine protective in mice","volume":"11","author":"Stadler","year":"2005","journal-title":"Emerg. Infect. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2020.106717_b0305","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/21645515.2015.1021527","article-title":"Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus","volume":"11","author":"Tang","year":"2015","journal-title":"Human Vacc. Immunotherapeut."},{"key":"10.1016\/j.intimp.2020.106717_b0310","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3389\/fimmu.2018.01093","article-title":"Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles","volume":"9","author":"Kim","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0315","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/21645515.2017.1296994","article-title":"Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection","volume":"13","author":"Wang","year":"2017","journal-title":"Human Vacc. Immunotherapeut."},{"key":"10.1016\/j.intimp.2020.106717_b0320","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","article-title":"A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection","volume":"499","author":"Tai","year":"2016","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0325","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/21645515.2015.1071455","article-title":"Safety and tolerability evaluation of the use of Montanide ISA\u2122 51 as vaccine adjuvant: a systematic review","volume":"12","author":"van Doorn","year":"2016","journal-title":"Human Vacc. Immunotherapeutics"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev. Vaccines"},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0335","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1128\/IAI.72.2.949-957.2004","article-title":"CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine","volume":"72","author":"Kumar","year":"2004","journal-title":"Infect. Immun."},{"issue":"8","key":"10.1016\/j.intimp.2020.106717_b0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011995","article-title":"Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity","volume":"5","author":"Graham","year":"2010","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.intimp.2020.106717_b0345","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-07-4619","article-title":"Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission","volume":"14","author":"Diefenbach","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2020.106717_b0350","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10875-011-9632-5","article-title":"Safety and immunogenicity of multimeric-001\u2014a novel universal influenza vaccine","volume":"32","author":"Atsmon","year":"2012","journal-title":"J. Clin. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2020.106717_b0355","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.vaccine.2006.01.058","article-title":"Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates","volume":"24","author":"Liu","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2020.106717_b0360","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2007.04.164","article-title":"Identification of synthetic vaccine candidates against SARS CoV infection","volume":"358","author":"Lien","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1479-0556-3-7","article-title":"A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses","volume":"3","author":"Azizi","year":"2005","journal-title":"Genetic Vacc. Therapy"},{"key":"10.1016\/j.intimp.2020.106717_b0370","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02357-13","article-title":"Identification of receptor-binding domain in S protein of the novel human coronavirus MERS-CoV as an essential target for vaccine development","author":"Du","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"npj Vaccines"},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0385","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.virol.2005.01.042","article-title":"Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein","volume":"334","author":"Bisht","year":"2005","journal-title":"Virology"},{"issue":"9988","key":"10.1016\/j.intimp.2020.106717_b0390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Rts","year":"2015","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2020.106717_b0395","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.intimp.2020.106717_b0400","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/cid\/ciq160","article-title":"An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers","volume":"52","author":"Van Braeckel","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.106717_b0405","doi-asserted-by":"crossref","unstructured":"Leroux-Roels, I., Forgus, S., De Boever, F., Clement, F., Demoiti\u00e9, M.A., Mettens, P., Moris, P., Ledent, E., Leroux-Roels, G., Ofori-Anyinam, O. and M72 Study Group, 2013. Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial.Vaccine,31(17), pp.2196-2206.","DOI":"10.1016\/j.vaccine.2012.05.035"},{"issue":"5","key":"10.1016\/j.intimp.2020.106717_b0410","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/vim.2010.0028","article-title":"Immunogenicity and protective efficacy in mice and hamsters of a \u03b2-propiolactone inactivated whole virus SARS-CoV vaccine","volume":"23","author":"Roberts","year":"2010","journal-title":"Viral Immunol."},{"issue":"Pt 6","key":"10.1016\/j.intimp.2020.106717_b0415","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1099\/vir.0.019190-0","article-title":"An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses","volume":"91","author":"Lobigs","year":"2010","journal-title":"J. General Virol."},{"issue":"44","key":"10.1016\/j.intimp.2020.106717_b0420","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax\u2122, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.intimp.2020.106717_b0425","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/glycob\/cwq201","article-title":"Delta inulin: a novel, immunologically active, stable packing structure comprising \u03b2-D-[2\u2192 1] poly (fructo-furanosyl) \u03b1-D-glucose polymers","volume":"21","author":"Cooper","year":"2011","journal-title":"Glycobiology"},{"issue":"36","key":"10.1016\/j.intimp.2020.106717_b0430","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","article-title":"Advax\u2122, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses","volume":"30","author":"Honda-Okubo","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0435","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0440","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of defined TLR ligands as adjuvants within human vaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0445","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1586\/14760584.2014.920236","article-title":"Toll-like receptor-based adjuvants: enhancing the immune response to vaccines against infectious diseases of chicken","volume":"13","author":"Gupta","year":"2014","journal-title":"Expert Rev. Vacc."},{"issue":"3","key":"10.1016\/j.intimp.2020.106717_b0450","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.00669-13","article-title":"Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines","volume":"21","author":"Gupta","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2020.106717_b0455","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1128\/JVI.00983-14","article-title":"Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine","volume":"88","author":"Iwata-Yoshikawa","year":"2014","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.intimp.2020.106717_b0460","doi-asserted-by":"crossref","first-page":"11416","DOI":"10.1128\/JVI.01410-12","article-title":"Intranasal treatment with poly (I\u00b7C) protects aged mice from lethal respiratory virus infections","volume":"86","author":"Zhao","year":"2012","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0465","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.vaccine.2004.07.031","article-title":"Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice","volume":"23","author":"Qu","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0470","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/vim.2007.0079","article-title":"Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine","volume":"21","author":"Gai","year":"2008","journal-title":"Viral Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0475","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12250-011-3183-z","article-title":"PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV","volume":"26","author":"Gai","year":"2011","journal-title":"Virologica Sinica"},{"key":"10.1016\/j.intimp.2020.106717_b0480","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2016.12.019","article-title":"Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice","volume":"140","author":"Wang","year":"2017","journal-title":"Antiviral Res."},{"issue":"38","key":"10.1016\/j.intimp.2020.106717_b0485","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1016\/j.vaccine.2011.06.100","article-title":"The immune responses of HLA-A* 0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI: C and R848","volume":"29","author":"Zhao","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0490","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vaccine.2006.06.084","article-title":"Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine","volume":"25","author":"Zakhartchouk","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0495","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vaccine.2016.11.064","article-title":"The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection","volume":"35","author":"Jiaming","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0500","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4049\/jimmunol.0800531","article-title":"Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells","volume":"182","author":"He","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0505","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.0141-9838.2004.00685.x","article-title":"Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity","volume":"26","author":"MacDonald","year":"2004","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.intimp.2020.106717_b0510","doi-asserted-by":"crossref","unstructured":"Wang, J., Tricoche, N., Du, L., Hunter, M., Zhan, B., Goud, G., Didier, E.S., Liu, J., Lu, L., Marx, P.A. and Jiang, S., 2012. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PloS one, 7(5).","DOI":"10.1371\/journal.pone.0037019"},{"issue":"39","key":"10.1016\/j.intimp.2020.106717_b0515","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.vaccine.2008.07.028","article-title":"Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines","volume":"26","author":"Xiao","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0520","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1743-422X-7-9","article-title":"An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses","volume":"7","author":"Zhao","year":"2010","journal-title":"Virology J."},{"issue":"26","key":"10.1016\/j.intimp.2020.106717_b0525","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1016\/j.vaccine.2005.01.098","article-title":"rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca volvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens","volume":"23","author":"MacDonald","year":"2005","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2020.106717_b0530","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0264-410X(01)00268-7","article-title":"Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge","volume":"20","author":"Plante","year":"2001","journal-title":"Vaccine"},{"issue":"27\u201328","key":"10.1016\/j.intimp.2020.106717_b0535","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1016\/j.vaccine.2004.03.035","article-title":"Protollin\u2122: a novel adjuvant for intranasal vaccines","volume":"22","author":"Jones","year":"2004","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2020.106717_b0540","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.4049\/jimmunol.1201194","article-title":"ICOS-expressing CD4 T cells induced via TLR4 in the nasal mucosa are capable of inhibiting experimental allergic asthma","volume":"189","author":"Shalaby","year":"2012","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106717_b0545","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/iai.63.6.2382-2386.1995","article-title":"Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection","volume":"63","author":"Mallett","year":"1995","journal-title":"Infect. Immun."},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0550","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1128\/IAI.69.7.4545-4553.2001","article-title":"Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults","volume":"69","author":"Fries","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2020.106717_b0555","doi-asserted-by":"crossref","unstructured":"Lambkin-Williams, R., Gelder, C., Broughton, R., Mallett, C.P., Gilbert, A.S., Mann, A., He, D., Oxford, J.S. and Burt, D., 2016. An intranasal proteosome-adjuvanted trivalent influenza vaccine is safe, immunogenic & efficacious in the human viral influenza challenge model. Serum IgG & mucosal IgA are important correlates of protection against illness associated with infection. PloS one, 11(12).","DOI":"10.1371\/journal.pone.0163089"},{"issue":"34","key":"10.1016\/j.intimp.2020.106717_b0560","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1016\/j.vaccine.2007.06.017","article-title":"Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice","volume":"25","author":"Hu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106717_b0565","doi-asserted-by":"crossref","unstructured":"Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z. and Gao, H., 2020. Development of an inactivated vaccine candidate for SARS-CoV-2.Science.","DOI":"10.1126\/science.abc1932"},{"key":"10.1016\/j.intimp.2020.106717_b0570","doi-asserted-by":"crossref","unstructured":"Ren, W., Sun, H., Gao, G.F., Chen, J., Sun, S., Zhao, R., Gao, G., Hu, Y., Zhao, G., Chen, Y. and Jin, X., 2020. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.bioRxiv. doi:https:\/\/doi.org\/10.1101\/2020.04.21.052209.","DOI":"10.1101\/2020.04.21.052209"},{"key":"10.1016\/j.intimp.2020.106717_b0575","doi-asserted-by":"crossref","unstructured":"Quinlan, B.D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M.S., Luo, G., Li, W., Zhong, G. and Choe, H., 2020. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement.IMMUNITY-D-20-00389. doi:https:\/\/doi.org\/10.1101\/2020.04.10.036418.","DOI":"10.1101\/2020.04.10.036418"},{"key":"10.1016\/j.intimp.2020.106717_b0580","unstructured":"http:\/\/investors.dynavax.com\/news-releases\/news-release-details\/dynavax-and-sinovac-announce-collaboration-develop-coronavirus (01.00 PM on 01\/05\/2020)."},{"key":"10.1016\/j.intimp.2020.106717_b0585","unstructured":"https:\/\/www.gsk.com\/en-gb\/media\/resource-centre\/our-contribution-to-the-fight-against-2019-ncov\/ (01.00 PM on 01\/05\/2020)."},{"key":"10.1016\/j.intimp.2020.106717_b0590","unstructured":"https:\/\/www.bioworld.com\/articles\/433029-australia-ramps-up-efforts-to-fight-coronavirus-with-genetic-sequence-in-hand (01.00 PM on 01\/05\/2020)."},{"key":"10.1016\/j.intimp.2020.106717_b0595","unstructured":"https:\/\/pipelinereview.com\/index.php\/2020040874282\/Vaccines\/Novavax-Identifies-Coronavirus-Vaccine-Candidate-Accelerates-Initiation-of-First-in-Human-Trial-to-Mid-May.html (01.00 PM on 01\/05\/2020)."},{"key":"10.1016\/j.intimp.2020.106717_b0600","unstructured":"https:\/\/www.contractpharma.com\/content-microsite\/covid-19\/2020-04-16\/soligenix-licenses-btgs-covaccine-ht-for-sars-cov-2 (01.00 PM on 01\/05\/2020)."},{"key":"10.1016\/j.intimp.2020.106717_b0605","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2016.09.008","article-title":"CoVaccine HT\u2122 adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1","volume":"439","author":"Lakhan","year":"2016","journal-title":"J. Immunol. Methods"},{"issue":"16","key":"10.1016\/j.intimp.2020.106717_b0610","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1128\/JVI.00549-10","article-title":"A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets","volume":"84","author":"Bodewes","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.106717_b0615","unstructured":"https:\/\/www.contractpharma.com\/contents\/view_breaking-news\/2020-04-13\/ibio-expands-covid-19-vaccine-collaboration\/ (05.00 PM on 08\/05\/2020)."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS ONE"},{"issue":"26","key":"10.1016\/j.intimp.2020.106717_b0625","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59\u2122 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.intimp.2020.106717_b0630","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative safety of vaccine adjuvants: a summary of current evidence and future needs","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf."},{"issue":"33","key":"10.1016\/j.intimp.2020.106717_b0635","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2016.05.071","article-title":"Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax\u2122 delta inulin adjuvant","volume":"34","author":"Gordon","year":"2016","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.intimp.2020.106717_b0640","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax\u2122, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106717_b0645","doi-asserted-by":"crossref","unstructured":"Saxena, M., Sabado, R.L., LAMAR, M., Mohri, H., Salazar, A., Dong, H., Correa Da Rosa, J., Markowitz, M., Bhardwaj, N. and Miller, E., 2019. Poly-ICLC, a TLR3 agonist, induces transient Innate Immune Responses in Patients with Treated HIV-Infection: A Randomised Double-blinded Placebo Controlled Trial.Frontiers in immunology,10, p.725.","DOI":"10.3389\/fimmu.2019.00725"},{"issue":"23","key":"10.1016\/j.intimp.2020.106717_b0650","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1158\/1078-0432.CCR-12-2189","article-title":"Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients","volume":"18","author":"Sabbatini","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2020.106717_b0655","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/med.21553","article-title":"Recent clinical trends in Toll-like receptor targeting therapeutics","volume":"39","author":"Anwar","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2020.106717_b0660","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.vaccine.2015.10.027","article-title":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults","volume":"34","author":"Santini-Oliveira","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106717_b0665","series-title":"CpG Oligodeoxynucleotides as adjuvants for clinical use. In Immunopotentiators in modern vaccines","first-page":"163","author":"Shirota","year":"2017"},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0670","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2007.02.025","article-title":"Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies","volume":"47","author":"Pockros","year":"2007","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0675","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.vaccine.2016.01.003","article-title":"Enhanced humoral response to influenza vaccine in aged mice with a novel adjuvant, rOv-ASP-1","volume":"34","author":"Jiang","year":"2016","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.intimp.2020.106717_b0680","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1016\/j.vaccine.2017.05.004","article-title":"Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice","volume":"35","author":"Cao","year":"2017","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.intimp.2020.106717_b0685","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.vaccine.2004.09.010","article-title":"A novel intranasal Protollin\u2122-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice","volume":"23","author":"Chabot","year":"2005","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.intimp.2020.106717_b0690","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2009.01.009","article-title":"Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine","volume":"44","author":"Huang","year":"2009","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0695","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1475-2875-10-182","article-title":"Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT\u2122 and Montanide ISA 51 in rhesus macaques","volume":"10","author":"Kusi","year":"2011","journal-title":"Malar. J."},{"issue":"5","key":"10.1016\/j.intimp.2020.106717_b0700","article-title":"Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT\u2122 protects against blood-stage challenge in rhesus macaques","volume":"6","author":"Hamid","year":"2011","journal-title":"PLoS ONE"},{"issue":"45","key":"10.1016\/j.intimp.2020.106717_b0705","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with Matrix M\u2122 adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.intimp.2020.106717_b0710","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.4161\/hv.29583","article-title":"Matrix MTM adjuvanted virosomal H5N1 vaccine induces balanced Th1\/Th2 CD4+ T cell responses in man","volume":"10","author":"Pedersen","year":"2014","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"9","key":"10.1016\/j.intimp.2020.106717_b0715","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.intimp.2020.106717_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","author":"Koch","year":"2020","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.intimp.2020.106717_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","author":"Folegatti","year":"2020","journal-title":"Lancet. Infect. Dis"},{"issue":"50","key":"10.1016\/j.intimp.2020.106717_b0730","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2020.106717_b0735","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/135965350701200702","article-title":"Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine","volume":"12","author":"Lin","year":"2007","journal-title":"Antiviral therapy"},{"issue":"24","key":"10.1016\/j.intimp.2020.106717_b0740","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/j.vaccine.2018.04.082","article-title":"Heterologous prime\u2013boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus","volume":"36","author":"Jung","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0745","doi-asserted-by":"crossref","first-page":"e01651","DOI":"10.1128\/JVI.01651-16","article-title":"Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants","volume":"91","author":"Tai","year":"2017","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106717_b0750","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2017.02.012","article-title":"MERS-CoV spike nanoparticles protect mice from MERS-CoV infection","volume":"35","author":"Coleman","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106717_b0755","unstructured":"https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40064-015-0972-0","article-title":"The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm","volume":"4","author":"Ghimire","year":"2015","journal-title":"Springerplus"},{"key":"10.1016\/j.intimp.2020.106717_b0765","first-page":"1","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools","author":"Fu","year":"2020","journal-title":"Virologica Sinica"},{"key":"10.1016\/j.intimp.2020.106717_b0770","doi-asserted-by":"crossref","unstructured":"Wu, D. and Yang, X.O., 2020. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.Journal of Microbiology, Immunology and Infection.","DOI":"10.1016\/j.jmii.2020.03.005"},{"issue":"5","key":"10.1016\/j.intimp.2020.106717_b0775","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106717_b0780","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/rmv.405","article-title":"Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications","volume":"13","author":"Takada","year":"2003","journal-title":"Rev. Med. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0785","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/088282403763635465","article-title":"Antibody-dependent enhancement of virus infection and disease","volume":"16","author":"Tirado","year":"2003","journal-title":"Viral Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0790","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"Wang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2020.106717_b0795","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106717_b0800","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","article-title":"Is COVID-19 receiving ADE from other coronaviruses?","volume":"22","author":"Tetro","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2020.106717_b0805","doi-asserted-by":"crossref","unstructured":"van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J., Port, J., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M. and Feldmann, F., 2020. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.bioRxiv.","DOI":"10.1101\/2020.05.13.093195"},{"issue":"1","key":"10.1016\/j.intimp.2020.106717_b0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2020.106717_b0815","doi-asserted-by":"crossref","unstructured":"Yu, J., Tostanoski, L.H., Peter, L., Mercado, N.B., McMahan, K., Mahrokhian, S.H., Nkolola, J.P., Liu, J., Li, Z., Chandrashekar, A. and Martinez, D.R., 2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.Science.","DOI":"10.1126\/science.abc6284"},{"key":"10.1016\/j.intimp.2020.106717_b0820","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","author":"Zhu","year":"2020","journal-title":"The Lancet"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920313862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920313862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:50:30Z","timestamp":1769028630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920313862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":164,"alternative-id":["S1567576920313862"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106717","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106717"}}